There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Check-Cap (NASDAQ:CHEK), Aptose Biosciences (NASDAQ:APTO) and Actinium Pharmaceuticals (NYSE:ATNM) with bullish sentiments.
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Check-Cap today and set a price target of $14. The company’s shares closed yesterday at $4, close to its 52-week low of $3.08.
“We note that Check-Cap is collaborating with GE Healthcare (GE; not rated) to manufacture C-Scan to be used in the U.S. pilot study. Details from the study design could be available in the coming weeks. Prevention (CDC), about one in three adults aged 50 to 75 years have not been tested for colorectal cancer (CRC), and there are more than 20M adults in the U.S. who haven’t had any recommended screening for colorectal cancer. In our view, C-Scan has the potential to increase the number of adults screened for CRC by eliminating common barriers such as unpleasant bowel preparation, and allow for early detection of polyps without the use of colonoscopy. In the wake of this update, we reiterate our Buy rating and $14 price target. C-Scan secured regulatory approval in Israel.”
According to TipRanks.com, Selvaraju is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -1.9% and a 33.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Bausch Health Companies Inc, and Synergy Pharmaceuticals Inc.
Check-Cap has an analyst consensus of Moderate Buy, with a price target consensus of $14.
See today’s analyst top recommended stocks >>
Aptose Biosciences (APTO)
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aptose Biosciences today and set a price target of $8.50. The company’s shares closed yesterday at $1.90.
“Valuation and impediments to achieving price target. We reiterate our Buy and $8.50 price target. Our target is based on our clinical net present value (NPV) model, which derives its value from both the CG-806 opportunity in AML and APTO-253 opportunity in AML and MDS. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.7% and a 35.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Aptose Biosciences is a Moderate Buy with an average price target of $7.75.
Actinium Pharmaceuticals (ATNM)
In a report released today, Jotin Marango from Roth Capital maintained a Buy rating on Actinium Pharmaceuticals, with a price target of $6. The company’s shares closed yesterday at $0.79, close to its 52-week high of $0.87.
“We believe that this new direction creates new opportunities for an existing asset towards quick clinical POC and potential collaboration with high-value partners. However, in our view, the more important takeaway is the company’s emerging new identity as a fundamental platform leveraging radiolabelled biologics for cellular conditioning (myeloablation, lymphodepletion) rather than direct therapeutics, which we view as differentiated and underappreciated.”
According to TipRanks.com, Marango is a 1-star analyst with an average return of -0.9% and a 36.5% success rate. Marango covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Stemline Therapeutics Inc, and Cyclacel Pharmaceuticals.
Currently, the analyst consensus on Actinium Pharmaceuticals is a Strong Buy with an average price target of $4.25, a 436.8% upside from current levels. In a report issued on September 27, Maxim Group also maintained a Buy rating on the stock with a $3 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.